Welcome and introductions

• Introduction to the AML Hub
• Webinar educational objectives and pre-webinar test questions
• Introduction to the speakers

FLT3 mutations in AML: Types, prevalence, and clinical significance

• An overview of FLT3 mutations in AML pathology, including their prevalence
• Distinction between FLT3-ITD- and -TKD-mutated AML and their mechanisms of disease
• Prognosis for patients with FLT3-ITD- and -TKD-mutated AML, including current risk stratification guidelines (e.g. ELN and NCCN)

Comparing treatment options for patients with FLT3-ITD and
-TKD mutations

• First- and second-generation FLT3 inhibitors for ITD- and TKD-mutated AML and their mechanisms of action
• Summary of key safety and efficacy data (e.g. from QuANTUM-FIRST, RATIFY, and ADMIRAL trials)
• Differences in efficacy and outcomes of FLT3 inhibitors in FLT3-ITD- vs -TKD-mutated AML

Implications for clinical practice: Managing AML with FLT3-ITD and -TKD mutations

• Importance of early and repeat genetic testing in AML
• Personalizing treatment: Tailoring therapy to FLT3 mutation subtype
• Managing relapse and resistance to FLT3 inhibitors, including secondary mutations and clonal evolution – key differences between FLT3-ITD- and -TKD-mutated AML
• Future perspectives for FLT3 inhibition in FLT3-ITD- and -TKD-mutated AML, including remaining unmet needs and challenges

Closing remarks

• Summary of key insights
• Q&A with audience
• Post-webinar test questions and evaluation
• Thank you and meeting close